Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Merck
Medtronic
Colorcon
Harvard Business School

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR ARRANON


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Arranon

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002970 ↗ 506U78 in Treating Patients With Refractory Hematologic Cancer Completed Children's Cancer Group Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗ 506U78 in Treating Patients With Refractory Hematologic Cancer Completed National Cancer Institute (NCI) Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00005080 ↗ 506U78 in Treating Patients With Lymphoma Completed National Cancer Institute (NCI) Phase 2 2000-05-01 Phase II trial to study the effectiveness of 506U78 in treating patients who have lymphoma that has not been treated previously or that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
NCT00005950 ↗ 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma Terminated National Cancer Institute (NCI) Phase 2 2000-04-01 Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
NCT00005982 ↗ 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma Terminated National Cancer Institute (NCI) Phase 2 2000-04-01 Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Arranon

Condition Name

Condition Name for Arranon
Intervention Trials
Recurrent Adult T-cell Leukemia/Lymphoma 2
Angioimmunoblastic T-cell Lymphoma 2
T Acute Lymphoblastic Leukemia 2
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Arranon
Intervention Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 7
Leukemia, Lymphoid 7
Leukemia 7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Arranon

Trials by Country

Trials by Country for Arranon
Location Trials
United States 80
Canada 11
Germany 9
Australia 8
New Zealand 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Arranon
Location Trials
Texas 8
California 5
Illinois 4
Ohio 3
Missouri 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Arranon

Clinical Trial Phase

Clinical Trial Phase for Arranon
Clinical Trial Phase Trials
Phase 3 1
Phase 2 7
Phase 1/Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Arranon
Clinical Trial Phase Trials
Completed 6
Recruiting 3
Terminated 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Arranon

Sponsor Name

Sponsor Name for Arranon
Sponsor Trials
National Cancer Institute (NCI) 9
GlaxoSmithKline 3
M.D. Anderson Cancer Center 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Arranon
Sponsor Trials
NIH 10
Other 9
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
AstraZeneca
McKinsey
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.